longer subject to

Form 5 obligations

may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
hours per response	0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Respons	ses)														
	me and Address of Reporting Person * WOTNIK DAVID P				2. Issuer Name and Ticker or Trading Symbol ACCESS PHARMACEUTICALS INC [accp]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
	(First) (Middle) HARMACEUTICALS INC, 2600 JS FRWY STE 176				3. Date of Earliest Transaction (Month/Day/Year) 05/24/2012					X Officer (give title below) Other (specify below) Sr. VP R&D					
(Street) DALLAS, TX 752072107				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							<u> </u>				
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date, if any (Month/Day/Year)			Code (Instr.)	3. Transaction Code (A) or Disposed (Instr. 8) (Instr. 3, 4 and 5) Code V Amount (D)		ed 5. Amount of Securities Beneficially			-	Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							in this form	o respond to are not requ valid OMB co	ired to res	spond u				1474 (9-02)	
		Table I					nired, Disposed o options, convert								
Security or Exercise (Month/Day/Year) any		Execution Date, if	Transaction I Code S (Instr. 8) I		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Expiration Date (Month/Day/Year) Ur		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		(Instr. 5) Benefic Owned Follow Report	Derivative Securities Beneficially Owned Following Reported	ive Owners es Form of ially Derivat Security ng Direct (d or Indir	Ownersh (Instr. 4)	
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s (Instr. 4)	(Instr. 4)		
Stock option (right to buy) \$ 0.61	05/24/2012		A		50,000		05/24/2012(1)	05/24/2022	Common	50,000	\$ 0.61	555,000	D		
Stock option (right to buy) \$ 18.65	03/22/2012		E			10,000	03/22/2002	03/22/2012	Common	10,000	\$ 18.65	545,000	D		
Reporting C	Owners		Relatio												

Donation Community (Addition	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
NOWOTNIK DAVID P ACCESS PHARMACEUTICALS INC 2600 STEMMONS FRWY STE 176 DALLAS, TX 752072107			Sr. VP R&D				

Signatures

David P. Nowotnik (by Stephen B. Thompson)	05/29/2012
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 12,500 stock options vest on each of 05/24/12, 11/24/12, 05/24/13 and 11/24/13

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.